Pre- and postoperative uses of CEA

Area of Science:

• Oncology
• Clinical Chemistry

Background:

• Carcinoid embryonic antigen (CEA) is a biomarker used in colorectal cancer management.
• The prognostic and monitoring capabilities of CEA require further elucidation.

Purpose of the Study:

• To evaluate the predictive and monitoring abilities of pre-operative plasma CEA levels in colorectal cancer patients.
• To assess the accuracy of CEA in detecting recurrence and guiding surgical decisions.

Main Methods:

• Plasma CEA levels were measured prior to definitive surgery in colorectal cancer patients.
• Consecutive CEA elevations (>2.5 ng/ml) were analyzed for recurrence detection.
• Second-look laparotomy was performed in patients with elevated CEA levels.

Main Results:

• Pre-operative CEA levels >2.5 ng/ml correlated with increased risk of local recurrence and metastatic disease.
• Using two consecutive CEA elevations (>2.5 ng/ml) detected recurrence earlier in one-third of patients, with a 15% false-positive rate.
• Second-look laparotomy in 14 patients with elevated CEA revealed disease in 11, with two cases being operable.

Conclusions:

• Pre-operative plasma CEA levels possess predictive value for colorectal cancer prognosis.
• CEA serves as a valuable monitor for detecting recurrence, though accuracy requires careful interpretation.
• Elevated CEA levels can indicate the need for further investigation, including second-look laparotomy, potentially identifying operable disease.